Testing a new drug for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests an experimental drug (TEV‑56278) alone or with another drug (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of solid tumor (like lung, colon, or breast cancer) that has spread or come back, and standard treatments haven't worked or aren't right for you.
- You are expected to live at least 12 more weeks.
- If you could become pregnant, you must use very effective birth control during the study and for 4 months after the last dose.
- If you are a man and could get a partner pregnant, you must use condoms and not donate sperm during the study and for 4 months after.
- You cannot have active brain tumors, autoimmune disease, serious infections, or certain heart or lung problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests ABX-001, a new immunotherapy, alone or with pembrolizumab, for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. It may help if your tumor has become resistant to previous immunotherapies.
This trial tests a new drug, BTM-3566, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
This trial tests a new drug called SKB500 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and may help shrink tumors.
This study tests a new drug (BGB-26808) alone or with another drug (tislelizumab) for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if the combination can help shrink tumors or slow their growth.
This trial is testing a new drug (BMS-986517) for people with advanced solid tumors, including certain lung, head and neck, and breast cancers. The goal is to see if the drug is safe and effective.
This early-phase study tests a new treatment in people with advanced (locally advanced or metastatic) solid tumors that have worsened or cannot be treated with standard therapies. It may help shrink tumors or slow growth, and it also helps doctors learn the safest way to use the medicine.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.